Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
ImmunoPrecise Antibodies Ltd. (IPA) had Return on Investments of -7.00% for the most recently reported fiscal quarter, ending 2025-04-30.
| Income Statement Financials | |
$4.94M |
|
$-1.77M |
|
$1.77M |
|
$3.17M |
|
$6.02M |
|
$-1.08M |
|
$-0.52M |
|
$-1.60M |
|
$-1.30M |
|
$-1.77M |
|
$-1.77M |
|
$-1.77M |
|
$-1.51M |
|
$-1.08M |
|
$-0.37M |
|
33.38M |
|
33.38M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$13.46M |
|
$11.31M |
|
$18.43M |
|
$31.89M |
|
$6.47M |
|
$8.29M |
|
$8.47M |
|
$14.93M |
|
$16.95M |
|
$10.28M |
|
$16.95M |
|
46.15M |
|
| Cash Flow Statement Financials | |
$-4.60M |
|
$-0.57M |
|
$10.69M |
|
$2.54M |
|
$7.74M |
|
$5.20M |
|
$0.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.08 |
|
-- |
|
-- |
|
0.33 |
|
0.57 |
|
64.11% |
|
-21.89% |
|
-21.89% |
|
-- |
|
-32.48% |
|
-35.79% |
|
$-5.17M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
1.18 |
|
1.62 |
|
55.67 |
|
-10.43% |
|
-17.19% |
|
-5.54% |
|
|
Return on Investments |
-7.00% |
$0.37 |
|
$-0.15 |
|
$-0.14 |
|